{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:51:02Z","timestamp":1770987062174,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1053\/j.ackd.2008.12.010","type":"journal-article","created":{"date-parts":[[2009,2,22]],"date-time":"2009-02-22T05:29:31Z","timestamp":1235280571000},"page":"117-130","source":"Crossref","is-referenced-by-count":66,"title":["Current and Upcoming Erythropoiesis-Stimulating Agents, Iron Products, and Other Novel Anemia Medications"],"prefix":"10.1053","volume":"16","author":[{"given":"Iain C.","family":"Macdougall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ashenden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2008.12.010_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V8.4.349.349","article-title":"Humoral regulation of red cell production","volume":"8","author":"Erslev","year":"1953","journal-title":"Blood"},{"key":"10.1053\/j.ackd.2008.12.010_bib2","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1093\/ndt\/gfm392","article-title":"Recombinant EPO production\u2014Points the nephrologist should know","volume":"22","author":"Jelkmann","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2008.12.010_bib3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(86)92192-6","article-title":"Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis","author":"Winearls","year":"1986","journal-title":"Lancet ii:"},{"key":"10.1053\/j.ackd.2008.12.010_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2008.12.010_bib5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/00041552-199411000-00010","article-title":"Monitoring of iron status and iron supplementation in patients treated with erythropoietin","volume":"3","author":"Macdougall","year":"1994","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ackd.2008.12.010_bib6","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1016\/S0021-9258(17)35756-3","article-title":"Structural characterization of human erythropoietin","volume":"261","author":"Lai","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ackd.2008.12.010_bib7","first-page":"449","article-title":"Erythropoietin levels in uremic nephric and anephric patients","volume":"93","author":"Caro","year":"1979","journal-title":"J Lab Clin Med"},{"key":"10.1053\/j.ackd.2008.12.010_bib8","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1016\/S0021-9258(19)63387-9","article-title":"Purification of human erythropoietin","volume":"252","author":"Miyake","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ackd.2008.12.010_bib9","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.82.22.7580","article-title":"Cloning and expression of the human erythropoietin gene","volume":"82","author":"Lin","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ackd.2008.12.010_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.1998.00521.x","article-title":"Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties","volume":"100","author":"Storring","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.ackd.2008.12.010_bib11","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1182\/blood.V98.13.3626","article-title":"Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin","volume":"98","author":"Skibeli","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.ackd.2008.12.010_bib12","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/ndt\/gfh800","article-title":"Erythropoietin receptors: their role beyond erythropoiesis","volume":"20","author":"Rossert","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2008.12.010_bib13","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1074\/jbc.M510493200","article-title":"Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP)","volume":"281","author":"Gross","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ackd.2008.12.010_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003088-199120020-00002","article-title":"Clinical\u00a0pharmacokinetics of epoetin (recombinant human erythropoietin)","volume":"20","author":"Macdougall","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.ackd.2008.12.010_bib15","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJM199808273390902","article-title":"Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis patients","volume":"339","author":"Kaufman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2008.12.010_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/ajkd.2002.34881","article-title":"Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients","volume":"40","author":"Besarab","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2008.12.010_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF01209934","article-title":"The role of carbohydrate on the biological activity of erythropoietin","volume":"10","author":"Egrie","year":"1993","journal-title":"Glycoconjugate J"},{"key":"10.1053\/j.ackd.2008.12.010_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nbt799","article-title":"Enhancement of therapeutic protein in vivo activities through glycoengineering","volume":"21","author":"Elliott","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.ackd.2008.12.010_bib19","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.V10112392","article-title":"Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients","volume":"10","author":"Macdougall","year":"1999","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"Suppl 4","key":"10.1053\/j.ackd.2008.12.010_bib20","doi-asserted-by":"crossref","first-page":"iv2","DOI":"10.1093\/ndt\/gfm160","article-title":"Pharmacology of darbepoetin alfa","volume":"22","author":"Macdougall","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2008.12.010_bib21","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1046\/j.1523-1755.2002.00657.x","article-title":"Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients","volume":"62","author":"Vanrenterghem","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2008.12.010_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/ajkd.2002.33919","article-title":"Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients","volume":"40","author":"Nissenson","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2008.12.010_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5414\/CNP63327","article-title":"Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease","volume":"63","author":"Ling","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ackd.2008.12.010_bib24","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/ndt\/gfh021","article-title":"Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients","volume":"19","author":"Jadoul","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2008.12.010_bib25","first-page":"436","article-title":"C.E.R.A. (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia","volume":"4","author":"Macdougall","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"10.1053\/j.ackd.2008.12.010_bib26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2165\/00003495-200868080-00009","article-title":"Methoxy polyethylene glycol-epoetin beta: A review of its use in the management of anaemia associated with chronic kidney disease","volume":"68","author":"Curran","year":"2008","journal-title":"Drugs"},{"key":"10.1053\/j.ackd.2008.12.010_bib27","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00730306","article-title":"Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease","volume":"1","author":"Macdougall","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2008.12.010_bib28","first-page":"211","article-title":"Dynepo\u00ae: An erythropoiesis-stimulating agent with a difference?","volume":"22","author":"Howard","year":"2008","journal-title":"Port J Nephrol Hypert"},{"key":"10.1053\/j.ackd.2008.12.010_bib29","unstructured":"The Court Service\u2013Court of Appeal\u2013Civil Judgement: In TKT's technology, those cells were designated as R223 cells. Neutral Citation Number: EWCA Civ.\u00a01096, 2002. Available at: www.hmcourtsservice.gov.uk\/judgmentsfiles\/j1329\/Kirin_v_Hoechst.htm."},{"key":"10.1053\/j.ackd.2008.12.010_bib30","doi-asserted-by":"crossref","first-page":"12045","DOI":"10.1073\/pnas.2131556100","article-title":"Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid","volume":"100","author":"Tangvoranuntakul","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ackd.2008.12.010_bib31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2215\/CJN.04251007","article-title":"The first biosimilar epoetin: but how similar is it?","volume":"3","author":"Schellekens","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2008.12.010_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2008.12.010_bib33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1592\/phco.2005.25.7.954","article-title":"Biosimilar epoetins: An analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins","volume":"25","author":"Combe","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.ackd.2008.12.010_bib34","first-page":"313A","article-title":"Gaps in the quality and potential safety of biosimilar epoetins in the developing world: an international survey","volume":"17","author":"Singh","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2008.12.010_bib35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.273.5274.464","article-title":"Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A","volume":"273","author":"Livnah","year":"1996","journal-title":"Science"},{"key":"10.1053\/j.ackd.2008.12.010_bib36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1126\/science.273.5274.458","article-title":"Small peptides as potent mimetics of the protein hormone erythropoietin","volume":"273","author":"Wrighton","year":"1996","journal-title":"Science"},{"key":"10.1053\/j.ackd.2008.12.010_bib37","first-page":"1034","article-title":"Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia","volume":"9","author":"Macdougall","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1053\/j.ackd.2008.12.010_bib38","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.exphem.2006.05.012","article-title":"Preclinical evaluation of hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia","volume":"34","author":"Fan","year":"2006","journal-title":"Exp Hematol"},{"issue":"Suppl 6","key":"10.1053\/j.ackd.2008.12.010_bib39","article-title":"Renal excretion is the primary route of elimination for the erythropoiesis stimulating agent hematide as assessed by quantitative whole-body autoradioluminography in Sprague Dawley rats","volume":"22","author":"Woodburn","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2008.12.010_bib40","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2006-04-015818","article-title":"Evaluation of the safety and pharmacodynamics of hematide, a novel erythropoietic agent, in a phase 1, double-blind placebo-controlled, dose-escalation study in healthy volunteers","volume":"108","author":"Stead","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.ackd.2008.12.010_bib41","article-title":"Hematide, a synthetic peptide-based erythropoiesis stimulating agent, achieves correction of anemia and maintains Hb in patients with CKD not on dialysis","author":"Macdougall","year":"2006","journal-title":"Ann Meet Am Soc Nephrol 39:Abs F-FC079"},{"key":"10.1053\/j.ackd.2008.12.010_bib42","article-title":"Hematide, a synthetic peptide-based erythropoiesis stimulating agent, maintains hemoglobin in hemodialysis patients previously treated with epoetin alfa (EPO)","author":"Besarab","year":"2007","journal-title":"Natl Kidney Found Clin Meet Abs 24, Orlando, FL, April 10-14,"},{"key":"10.1053\/j.ackd.2008.12.010_bib43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.exphem.2007.05.007","article-title":"Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model","volume":"35","author":"Woodburn","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1053\/j.ackd.2008.12.010_bib44","article-title":"Treatment of erythropoietin antibody-mediated pure red cell aplasia with a novel synthetic peptide-based erythropoietin receptor agonist","author":"Macdougall","year":"2007","journal-title":"J Am Soc Nephrol 18:80A,"},{"key":"10.1053\/j.ackd.2008.12.010_bib45","first-page":"643","article-title":"An optimized supravalent EPO mimetic peptide with unprecedented efficacy","volume":"85","author":"P\u00f6tgens","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1053\/j.ackd.2008.12.010_bib46","doi-asserted-by":"crossref","first-page":"12156","DOI":"10.1073\/pnas.96.21.12156","article-title":"Mimicry of erythropoietin by a nonpeptide molecule","volume":"96","author":"Qureshi","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ackd.2008.12.010_bib47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2215\/CJN.03840907","article-title":"Novel erythropoiesis-stimulating agents: A new era in anemia management","volume":"3","author":"Macdougall","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2008.12.010_bib48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semnephrol.2006.05.009","article-title":"Iron supplementation in renal anemia","volume":"26","author":"Fishbane","year":"2006","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ackd.2008.12.010_bib49","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2008.12.010_bib50","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI100478","article-title":"Quantitative aspects of iron deficiency in hypochromic anemia (the parenteral administration of iron)","volume":"6","author":"Heath","year":"1932","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ackd.2008.12.010_bib51","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1001\/jama.243.17.1726","article-title":"Intravenous iron dextran in clinical medicine","volume":"243","author":"Hamstra","year":"1980","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2008.12.010_bib52","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ajh.21154","article-title":"Intravenous iron: From anathema to standard of care","volume":"83","author":"Auerbach","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1053\/j.ackd.2008.12.010_bib53","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"Spinowitz","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2008.12.010_bib54","unstructured":"AMAG: Data on file\u2013safety study 62, 745\u2013748"},{"key":"10.1053\/j.ackd.2008.12.010_bib55","unstructured":"Ferinject Summary of Product Characteristics, 2007"},{"key":"10.1053\/j.ackd.2008.12.010_bib56","first-page":"814A","article-title":"A randomized controlled trial comparing IV ferric carboxymaltose (FCM) to oral iron in anemic patients with non-dialysis-dependent CKD","volume":"18","author":"Qunibi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2008.12.010_bib57","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1046\/j.1523-1755.1999.00436.x","article-title":"Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis","volume":"55","author":"Gupta","year":"1999","journal-title":"Kidney Int"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559508002176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559508002176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T05:03:36Z","timestamp":1633151016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559508002176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S1548559508002176"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2008.12.010","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}